SGYP

Synergy Pharmaceuticals, Inc. Press Releases

$3.77
*  
unch
unch
Get SGYP Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading SGYP now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SGYP After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation
7/17/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
7/14/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Plecanatide in Irritable Bowel Syndrome with Constipation
7/8/2014 6:00:00 AM - Business Wire

ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
7/8/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals Appoints Paul Eng, Ph.D., as Senior Vice President, Drug Development
5/29/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals’ Chairman and CEO, Dr. Gary S. Jacob, Awarded Honorary Degree by the University of Missouri – St. Louis
5/15/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals to Present at 2014 UBS Global Healthcare Conference
5/14/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals Reports First Quarter 2014 Financial Results: Cash and Investments Increase to $70.6 million as of March 31, 2014
5/13/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals to Give Plenary Presentation at the 16th Annual TIDES Summit
5/12/2014 10:26:00 AM - Business Wire

Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
5/8/2014 2:30:00 PM - PR Newswire

Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week 2014
5/1/2014 1:30:00 PM - Business Wire

Synergy Pharmaceuticals Announces Positive Results of Plecanatide Phase 2b Study in Patients with Irritable Bowel Syndrome with Constipation
4/30/2014 6:00:00 AM - Business Wire

Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
4/28/2014 6:00:00 AM - Business Wire